SCHEMBL6507972

SCHEMBL6507972

CCNS(=O)(=O)c1cc(Cl)ccc1C1(O)CCN(Cc2cccc(Oc3ccccc3)c2)CC1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR8 P51685 7/20 0.63
KCNH2 Q12809 2/20 0.51
ALDH1A1 P00352 2/20 0.48
FAAH O00519 6/20 0.47
KDM4E B2RXH2 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 1/20 0.45
ADAMTS4 O75173 1/20 0.45
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45
MMP3 P08254 1/20 0.45
MMP7 P09237 1/20 0.45
MMP9 P14780 1/20 0.45
MMP8 P22894 1/20 0.45
MMP13 P45452 1/20 0.45
MMP14 P50281 1/20 0.45
ADAM17 P78536 1/20 0.45
ADAMTS5 Q9UNA0 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6504810 0.91 CCR8 (0.77) CCR8KCNH2ALDH1A1
SCHEMBL6509206 0.90 CCR8 (0.64) CCR8KCNH2ALDH1A1FAAHKDM4E
SCHEMBL6506653 0.90 CCR8 (0.70) CCR8KCNH2ALDH1A1FAAHKDM4E
SCHEMBL7065039 0.89 CCR8 (0.68) CCR8KCNH2ALDH1A1FAAHKDM4E
SCHEMBL7064954 0.84 CCR8 (0.70) CCR8KCNH2ALDH1A1FAAHKDM4E
SCHEMBL6501070 0.84 CCR8 (0.86) CCR8KCNH2ALDH1A1FAAHKDM4E
SCHEMBL6503641 0.84 CCR8 (0.65) CCR8KCNH2ALDH1A1FAAH
SCHEMBL6505643 0.82 CCR8 (0.78) CCR8KCNH2ALDH1A1MMP1MMP9
SCHEMBL6501296 0.81 CCR8 (0.86) CCR8KCNH2MMP1MMP9MMP13
SCHEMBL6496975 0.80 CCR8 (0.57) CCR8KCNH2ALDH1A1FAAHKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143372-A1 Compounds, pharmaceutical compositions and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2005-06-30 US disclosed
WO-2003037271-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS,INC. (US) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143372-A1 Compounds, pharmaceutical compositions and methods of use therefor CCR8, CCL11, CCR5 CCR8 1/4885KCNH2 4349/4885ALDH1A1 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.